Prevalence of human papillomavirus in self-taken samples from screening nonattenders

J. U.H. Lam, M. Rebolj, D. M. Ejegod, H. Pedersen, C. Rygaard, E. Lynge, E. Harder, L. T. Thomsen, S. K. Kjaer, J. Bonde*

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    The Copenhagen Self-Sampling Initiative (CSi) has shown how human papillomavirus (HPV)-based self-sampling can be used to increase screening participation among 23,632 nonattenders in the Capital Region of Denmark. In this study, we describe HPV prevalence and genotype frequency in 4,824 self-samples as determined by three HPV assays (the CLART, Onclarity, and Hybrid Capture 2 [HC2] assays) and compare the results with those for physician-taken follow-up samples. The HPV self-sample findings were also compared to the findings for a reference population of 3,347 routinely screened women from the Horizon study, which had been undertaken in the same screening laboratory. Nonattenders had an HPV prevalence of 11.3% as determined by the CLART assay, which was lower than that for women from the Horizon study (18.5%). One-third of the CSi women who tested HPV positive by self-sampling tested HPV negative on the physician-taken follow-up sample. The CLART and Onclarity assays agreed on 64% (95% confidence interval [CI], 60 to 68%) of the HPV-positive self-taken samples. When the HC2 assay results were added into a three-way comparison, the level of agreement decreased to 27% (95% CI, 24 to 29%). Our findings suggest that further validation of HPV assays on self-taken samples is needed for optimal HPV detection and correct clinical management of HPV-positive women.

    Sider (fra-til)2913-2923
    Antal sider11
    TidsskriftJournal of Clinical Microbiology
    Udgave nummer10
    StatusUdgivet - okt. 2017


    Udforsk hvilke forskningsemner 'Prevalence of human papillomavirus in self-taken samples from screening nonattenders' indeholder.